AP01
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 85 | 特発性間質性肺炎 | 3 |
85. 特発性間質性肺炎
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
Showing 1 to 3 of 3 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-005103-39-PL (EUCTR) | 24/04/202120210424 | 24/03/202120210324 | Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interst ... | Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interst ... | Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10022611;Term: Interstitial lung disease;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) M ... | Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE Other descriptive name: NA Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE O ... | Avalyn Pharma, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | Czechia;Czech Republic;Poland;Australia;Netherlands;United Kingdom;New Zealand | ||
| 2 | EUCTR2020-005103-39-NL (EUCTR) | 21/04/202120210421 | 07/01/202120210107 | Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interst ... | Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interst ... | Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10022611;Term: Interstitial lung disease;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) M ... | Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE Other descriptive name: NA Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE O ... | Avalyn Pharma, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | Czechia;Czech Republic;Poland;Australia;Netherlands;United Kingdom;New Zealand | ||
| 3 | EUCTR2020-005103-39-CZ (EUCTR) | 16/04/202120210416 | 22/12/202020201222 | Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interst ... | Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interst ... | Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10022611;Term: Interstitial lung disease;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) M ... | Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE Other descriptive name: NA Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE O ... | Avalyn Pharma, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | Czechia;Czech Republic;Poland;Australia;Netherlands;United Kingdom;New Zealand |